CRISPR Therapeutics
CRSPNASDAQHigh RiskCRISPR/Cas9 gene editing technology enabling precise, permanent changes to DNA. The company's approach allows one-time treatments that can potentially cure genetic diseases by editing the root cause at the genomic level.
Market cap
Mid cap
Cash position
$4.2B as of Q4 2025
48 months runway
Revenue status
early revenue
Pipeline assets
4 programs
What does CRISPR Therapeutics do?
CRISPR Therapeutics is, quite literally, the company that brought gene editing from science fiction to reality. They co-developed the first-ever CRISPR-based medicine approved anywhere in the world — Casgevy, a one-time treatment for sickle cell disease and a blood disorder called beta-thalassemia. Here's how it works in simple terms: they take a patient's own blood stem cells out of their body, use CRISPR gene editing scissors to fix the genetic defect, and put them back. The edited cells then produce healthy hemoglobin for what appears to be the rest of the patient's life. It's as close to a cure as medicine has ever gotten for these diseases. For investors, the big questions right now are commercial ones, not scientific ones. Casgevy works — we know that. The question is whether enough patients can actually access a treatment that requires weeks of hospitalization and harsh pre-conditioning chemotherapy. Revenue ramp speed is everything. Beyond Casgevy, CRISPR is working on something potentially much bigger: off-the-shelf cancer cell therapies. Current CAR-T treatments like Yescarta require custom-manufacturing each dose from the patient's own cells, which takes weeks and costs $400K+. If CRISPR can make a universal version using gene-edited donor cells, it could dramatically expand who can be treated. They're also quietly working on what could be a cure for Type 1 diabetes using gene-edited insulin-producing cells — extremely early but the ultimate homerun if it works. With $4.2 billion in cash, CRISPR can fund everything in their pipeline for years without raising money. The stock trades well below that cash value plus Casgevy's projected revenues, which means the market is essentially giving you the entire pipeline for free.
What to watch
Casgevy quarterly revenue — look for acceleration in patient starts and new qualified treatment centers. Revenue above $100M/quarter would signal the ramp is working
CTX110 allogeneic CAR-T duration of response data — complete response rates matter, but how long responses last is what determines if allo CAR-T is commercially viable
Treatment center expansion pace — Casgevy can only grow as fast as the infrastructure to deliver it. Track QTC announcements closely
Competitor moves in allo CAR-T — if Allogene or Caribou report strong data, it validates the field but also means more competition for CRSP
Any insulin independence signals from the VCTX210 diabetes trial — even one patient showing sustained insulin production would be a major catalyst
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Casgevy (exagamglogene autotemcel) | Sickle cell disease and transfusion-dependent beta-thalassemia | Approved | Commercial — approved Dec 2023 | ▼ |
| CTX110 | Relapsed/refractory B-cell malignancies (large B-cell lymphoma) | Phase 2 | 2026 | ▼ |
| CTX112 | Relapsed/refractory B-cell malignancies (next-gen allogeneic CAR-T) | Phase 1 | H2 2026 | ▼ |
| VCTX210 | Type 1 diabetes | Phase 1 | 2026-2027 | ▼ |
Investment thesis
Bull case
CRISPR Therapeutics owns the first approved CRISPR medicine in history — that alone gives it a permanent place in biotech. Casgevy is ramping in both SCD and beta-thalassemia, and every additional qualified treatment center accelerates the revenue curve. The $4.2B cash position means they can fund the entire pipeline without dilution for 4+ years. The allogeneic CAR-T programs, if they work, represent a far larger market than Casgevy. And the diabetes program, while early, targets a condition affecting millions. CRSP trades at a significant discount to its cash + Casgevy NPV, meaning the entire pipeline is essentially free in the current stock price. If any one of the pipeline programs hits, the stock re-rates substantially.
Bear case
Casgevy's commercial ramp has been slower than hoped — the myeloablative conditioning regimen is harsh, qualified treatment centers are limited, and payer coverage remains inconsistent. The allogeneic CAR-T space has been a graveyard of failed programs; Allogene's struggles show how hard it is to make off-the-shelf cell therapy work. Each quarterly revenue miss for Casgevy reinforces the bear narrative that gene editing cures are too complex to scale commercially. The $180M quarterly burn rate, while sustainable with current cash, means CRSP needs Casgevy to ramp meaningfully or they'll eventually need to raise. And if CTX110 Phase 2 data disappoints, the oncology thesis collapses.
Key upcoming catalysts
Casgevy Q1 2026 revenue report (commercial ramp trajectory)
May 2026
CTX110 Phase 2 updated data in relapsed/refractory LBCL
H1 2026
CTX112 Phase 1 initial data
H2 2026
VCTX210 Type 1 diabetes Phase 1 update
2026
Casgevy label expansion (additional indications or geographies)
2026-2027
Risk factors
Casgevy commercial ramp continues to underwhelm due to treatment complexity and limited qualified centers
Allogeneic CAR-T (CTX110) fails to show durable responses in Phase 2, invalidating the off-the-shelf thesis
Bluebird bio's Lyfgenia gains commercial traction at Casgevy's expense in sickle cell disease
Regulatory or safety signals emerge from real-world Casgevy use that weren't apparent in clinical trials
Type 1 diabetes program faces insurmountable immune rejection challenges despite CRISPR hypoimmune edits
Comparable companies
Financial snapshot
Cash
$4.2B as of Q4 2025
Quarterly burn
$180M
Cash runway
48 months
Revenue
early revenue
Institutional ownership
68%
Recent offering
No recent dilution — well-capitalized from prior raises and Vertex milestones
Sponsored
Get premium CRSP analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you